Loading...
•
Sep 30, 2021
Orthofix Q3 2021 Earnings Report
Reported net sales of $112 million with adjusted EPS of $0.10.
Key Takeaways
Orthofix Medical Inc. reported a 1.3% increase in net sales to $112 million for the quarter ended September 30, 2021. The company's EPS was $(0.11), and adjusted EPS was $0.10.
Net sales increased by 1.3% over the prior year period, reaching $112 million.
Global Spinal Implants and Orthopedics businesses experienced double-digit growth.
Over 60,000 M6-C artificial cervical discs have been implanted worldwide.
AccelStim PMA application was submitted for healing fresh fractures.
Orthofix
Orthofix
Orthofix Revenue by Segment
Revenue by Segment
Bone Growth Therapies Revenue
CapyFin.comSpinal Implants, Biologics and Enabling Technologies Revenue
CapyFin.comGlobal Spine Revenue
CapyFin.comGlobal Orthopedics Revenue
CapyFin.com Forward Guidance
The Company expects net sales between $460.0 and $464.0 million for the year ended December 31, 2021.
Positive Outlook
- Continued strength of the M6-C disc.
- Growth of the FITBONE system.
- Recently bolstered 3D-printed titanium spinal interbody portfolio.
- Diversification of biologics portfolio with products like Opus Mg Set.
- Planned expansion of bone growth therapy portfolio with AccelStim.
Challenges Ahead
- Ongoing challenges of COVID on operations and financial results.
- Potential delays or cancellations of surgeries due to hospital limitations.
- Possible workforce disruptions due to illness, quarantines, or government actions.
- Potential disruptions to the supply chain.
- General economic weakness affecting customer spending.
Revenue & Expenses
Visualization of income flow from segment revenue to net income